Almac - The A to ZED of Automated Walleting for Clinical Trial Supply

CRAIGAVON, Northern Ireland, March 16, 2011 - Global Clinical Services provider Almac has announced an investment in
two ZED automated inline wallet presses. Operating in Craigavon and
Pennsylvania, the fully automated machines will drastically reduce timelines
associated with the use of blister card packaging, when compared with current
rotary press methods.

The automation on the machine allows for accurate placement of blister
strips into the wallet cards. The location and orientation of the blisters is
then verified by a vision system prior to sealing the card. This helps to
keep rejects to a minimum and maximises yield on product. This is the latest
development in an ongoing campaign by Almac to continually invest in
automation as a boost in efficiency and capacity to core primary packaging
services.

Commenting on the new machines, Almac's Global VP of Business Development
Martin Lamb said "The machines are a welcomed addition to Almac's growing
portfolio of automated primary packaging services as they demonstrate the
company's continued commitment to innovation and driving improvements across
the clinical supply chain. These lines are ideal for larger Phase III trials
that can require higher volumes of wallet cards. Also product pooling and
using supplies across multiple protocols can drive card quantities past the
traditional smaller volumes required for clinical supply. This allows us to
provide the client with the right option for their study."

The investment comes at a time when Almac is gearing up for the official
opening of their New North American Headquarters facility. The $120 million
project, which began in Summer 2008 is now operational with the official
opening of the 240,000 square foot premises planned for May 2011.

With over 20 years experience in clinical supply management
(www.almacgroup.com/clinicalservices/clinical-supply-management.aspx)
Almac is recognised as a strategic partner in the clinical supply process by
pharma and biotech companies across the world. These recent investments are a
sign of their dedication to offer market driven solutions to their customers.

Notes to Editors

About Almac Group

The Almac Group offers a broad range of services from R&D, biomarker
discovery and development, API manufacture, pharmaceutical development,
clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale
manufacture and packaging. Almac provides services to more than 600
companies, including all the world leaders in the pharmaceutical and biotech
sectors.

The company employs almost 3,000 individuals and is headquartered in
Craigavon, Northern Ireland. US operations are based in Pennsylvania, North
Carolina and California. Staff has now transferred to Almac's new $120m North
American Headquarters which is now fully operational.

For more information about the Almac Group, please visit
www.almacgroup.com or e-mail info@almacgroup.com

Contact: Tristan Jervis, DeFacto, T.Jervis at Defacto.com, Tel: +44-2078-613019